The Team

Dr Andrew Regan is a Saint Barths based British born polar explorer and entrepreneur. He is the founder and Chief Executive Officer of Corvus Capital.

Dr Regan sold Hobson Plc in 1996 for £154 million by way of a recommended cash takeover. In the years after the sale of Hobson Plc, Dr Regan continued to invest in a number of public and private companies and was a founding shareholder in ASOS, Virtual Internet, Imperial Energy and many more. These companies, along with several others from his portfolio, went on to receive a valuation or exit in excess of $1 billion.

In September 2004, he listed Corvus Capital on the London Stock Exchange as an investment vehicle and by 2005 the Company reached record profits of £22.1 million. Corvus was privatised in 2008 and continues to invest across a number of sectors.

Dr Regan has a strong interest in the use of bio-inspired science to create solutions for present day problems. In 2014 he was awarded a PhD for his research in writing and developing a bio-inspired algorithm for forecasting the financial markets. His thesis was "A system to predict the S&P 500 using a bio-inspired algorithm" which forecasted tomorrow's (t+1) directional trend of the S&P 500 at 55.1%.

He is passionate about the polar regions and is an accomplished polar explorer having lead a number of expeditions to both the Arctic and Antarctica.

Jamie has worked with Corvus since 2007 and has led a number of reverse takeover transactions, stock market listings, initial public offerings, secondary fundraisings, and merger transactions.

Jamie's prior transaction experience includes advising several special purpose acquisition vehicles in listing on the London Stock Exchange, including the listing of Bermele Plc, a special purpose acquisition vehicle, and the subsequent acquisition of Bermele by East Imperial Pte. Ltd., a global purveyor of ultra-premium beverages, in June 2019; the listing of Leverett Plc, which subsequently acquired Nuformix Plc, a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing; and Cizzle Biotechnology Holdings Plc, a UK-based diagnostics developer.

Jamie graduated from the University of Bristol with a BSc in Economics & Finance.

Lucius joined Corvus as an Analyst in September 2019 and is responsible for assisting on all transactions and managing existing client relationships.

Lucius' prior transaction experience includes assisting with a number of special purpose acquisition vehicles in listing on the London Stock Exchange, including the listing of Bermele Plc, a special purpose acquisition vehicle, and the subsequent acquisition of Bermele by East Imperial Pte. Ltd. in 2019. He also assisted with the listing of Cizzle Biotechnology Holdings Plc, a UK-based diagnostics developer.

Kathy has worked with Corvus since 2006 as an Executive Assistant and assists the team on all transactions.